Tango Therapeutics, Inc. Tango Therapeutics, Inc.

Tango Therapeutics, Inc.

TNGX

Classificação em ações #4534
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and... Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
Preço da ação
$27.18
Última sincronização: 2026-07-31
Valor de mercado
$3.38B
Variação (1 dia)
-1.41%
Variação (1 ano)
197.05%
País
US
Negociar Tango Therapeutics, Inc. (TNGX)

Categoria

Healthcare
EPS de Tango Therapeutics, Inc. (TNGX)
EPS em June 2026 TTM: $-0.85
De acordo com os últimos relatórios financeiros e o preço das ações da Tango Therapeutics, Inc., o EPS atual da empresa (TTM) é $-0.85. No final de 2023, a empresa teve um EPS de $-1.08, uma diminuição em relação a ao EPS de 2022, que foi de $-1.23.
Histórico de EPS da Tango Therapeutics, Inc. de 2019 até 2026
EPS no final de cada ano
Ano EPS Alterar
2026 (TTM) $-0.85 -28.57%
2024 $-1.19 10.19%
2023 $-1.08 -12.20%
2022 $-1.23 30.85%
2021 $-0.94 -41.98%
2020 $-1.62 3.18%
2019 $-1.57 0.00%
EPS de empresas semelhantes ou concorrentes
Empresa EPS Diferença de EPS País
$17.32 -2,137.65%
US
$-7.98 838.82%
US
$-5.29 522.35%
AU
- -
CH
$27.74 -3,363.53%
NL